Afluria PF Pediatric Quadrivalent is primarily used to protect children from seasonal influenza viruses. By administering the vaccine, healthcare providers aim to reduce the incidence of influenza infection among pediatric populations, thereby lowering the risk of associated complications and hospitalizations. This use is particularly crucial during flu season, when influenza viruses are most prevalent.

Beyond individual protection, vaccinating children with Afluria PF Pediatric Quadrivalent contributes to the establishment of community immunity.

By reducing the transmission of influenza viruses among children, especially those in high-risk groups, such as daycare attendees or school-aged children, the vaccine helps safeguard vulnerable populations within communities.

This indirect protection is essential for individuals who may not be eligible for vaccination or have compromised immune systems, including the elderly and individuals with certain medical conditions.

How it works 

Afluria PF Pediatric Quadrivalent works by stimulating the immune system to produce antibodies against the influenza viruses contained in the vaccine. These antibodies are specific to the strains included in the vaccine and are designed to recognize and target the virus if the individual is exposed to it in the future.

When Afluria PF Pediatric Quadrivalent is administered via injection, the antigens from the inactivated influenza viruses in the vaccine trigger an immune response in the body. Immune cells, such as B lymphocytes, recognize these antigens as foreign invaders and initiate the production of antibodies tailored to combat them.

Over time, the immune system builds up a reservoir of these antibodies, providing a defense mechanism against the influenza viruses included in the vaccine. If the vaccinated individual comes into contact with the influenza virus strains covered by the vaccine, their immune system can quickly recognize and neutralize the virus, reducing the severity and duration of illness.

Side effects of Afluria PF Pediatric Quadrivalent are typically mild and transient, but some individuals may experience more serious reactions. Here’s an overview:

Common Side Effects:

• Soreness, Redness, or Swelling at the Injection Site: Mild discomfort or tenderness at the site of injection is common and usually resolves within a few days.
• Fever: Low-grade fever may occur in some individuals as a natural response to the vaccine.
• Headache: Headaches are occasionally reported after vaccination but are generally mild and short-lived.
• Muscle Aches: Some individuals may experience muscle aches or general feelings of fatigue after receiving the vaccine.

Serious Side Effects:

• Severe Allergic Reactions: While rare, some individuals may experience a severe allergic reaction known as anaphylaxis shortly after vaccination..
• Guillain-Barré Syndrome (GBS): In extremely rare cases, vaccination with Afluria PF Pediatric Quadrivalent may be associated with the development of Guillain-Barré Syndrome.

Precautions and warnings should be considered before administering Afluria PF Pediatric Quadrivalent to ensure the safety and efficacy of the vaccine. 

Individuals with a history of severe allergic reactions (anaphylaxis) to any component of the vaccine should not receive Afluria PF Pediatric Quadrivalent. Vaccination should be postponed for individuals with a fever or acute illness until they have recovered, as the vaccine’s effectiveness may be compromised in such cases.

Close monitoring is recommended for individuals with a history of Guillain-Barré Syndrome, as vaccination may rarely be associated with the development or exacerbation of this neurological disorder. Allergic Reactions:may occur shortly after vaccination. Healthcare providers should be prepared to manage such reactions promptly.

Although rare, cases of Guillain-Barré Syndrome have been reported following vaccination with influenza vaccines. Individuals with a history of GBS should consult with their healthcare provider before receiving Afluria PF Pediatric Quadrivalent.

Drugs that weaken the immune system, such as corticosteroids or chemotherapy agents, may reduce the effectiveness of Afluria PF Pediatric Quadrivalent. 

Healthcare providers should evaluate the need for vaccination in individuals receiving immunosuppressive therapy and consider potential adjustments to the vaccination schedule to optimize immune response.

While antiviral medications are not known to interact directly with Afluria PF Pediatric Quadrivalent, healthcare providers should be aware of any concurrent use of antiviral medications for the treatment or prophylaxis of influenza. 

Antiviral therapy may be indicated in certain situations, such as influenza outbreaks or high-risk exposures, and should be managed in conjunction with vaccination efforts.

Dosage guidelines for Afluria PF Pediatric Quadrivalent are crucial for ensuring children receive optimal protection against influenza. Children aged 6 months through 8 years who are being vaccinated against influenza for the first time require two doses of the vaccine. 

These doses should be administered at least four weeks apart to allow the immune system ample time to mount a robust response. This two-dose schedule is particularly important for younger children, as they may have had limited prior exposure to influenza viruses.

For children aged 9 years and older, a single dose of Afluria PF Pediatric Quadrivalent is typically sufficient for vaccination. This single dose induces a strong immune response, providing protection against influenza for the duration of the flu season.

Afluria PF Pediatric Quadrivalent 2021-2022 is typically administered by healthcare professionals in clinical settings and may require a prescription depending on local regulations. Parents should consult their child’s healthcare provider for guidance on vaccination schedules and requirements.

• A prescription may be required for Afluria PF Pediatric Quadrivalent depending on local regulations and healthcare provider recommendations.
• Healthcare professionals typically administer the vaccine, ensuring it is given under proper supervision.
• Availability of the vaccine may vary based on regional guidelines and healthcare facility policies.
• Parents or guardians should consult with a healthcare provider to determine the most suitable vaccination schedule for their child.

Note: While some vaccines may be accessible without a prescription in specific settings, such as pharmacies or community clinics, Afluria PF Pediatric Quadrivalent may necessitate a prescription to ensure administration under qualified healthcare supervision.